Does GLOFITAMAB Cause Interstitial lung disease? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Interstitial lung disease have been filed in association with GLOFITAMAB (Columvi). This represents 0.6% of all adverse event reports for GLOFITAMAB.
7
Reports of Interstitial lung disease with GLOFITAMAB
0.6%
of all GLOFITAMAB reports
1
Deaths
1
Hospitalizations
How Dangerous Is Interstitial lung disease From GLOFITAMAB?
Of the 7 reports, 1 (14.3%) resulted in death, 1 (14.3%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GLOFITAMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does GLOFITAMAB Cause?
Cytokine release syndrome (415)
Disease progression (183)
Off label use (129)
Death (125)
Neutropenia (109)
Pyrexia (78)
Febrile neutropenia (69)
Covid-19 (62)
Drug ineffective (53)
Immune effector cell-associated neurotoxicity syndrome (45)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which GLOFITAMAB Alternatives Have Lower Interstitial lung disease Risk?
GLOFITAMAB vs GLOFITAMAB-GXBM
GLOFITAMAB vs GLUCAGON
GLOFITAMAB vs GLUCAGON\GLUCAGON\WATER
GLOFITAMAB vs GLUCARPIDASE
GLOFITAMAB vs GLUCOPHAGE